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Natural killer (NK) cells are innate lymphocytes that are thought to kill cells that down-regulate MHC class I (MHC-I) 
through “missing-self” recognition. NK cells from B2m−/− mice that lack surface MHC-I, however, are not autoreactive as 
predicted by the missing-self hypothesis. As a result, it is unclear if MHC-I down-regulation in vivo induces NK cell reactivity 
or tolerance to missing-self. Here, we generated a floxed B2m mouse to acutely down-regulate MHC-I in vivo in a host that 
normally expresses MHC-I. Global down-regulation of MHC-I induced NK cell hyporesponsiveness and tolerance to missing-
self without overt missing-self reactivity. In contrast, down-regulation of MHC-I on a small fraction of hematopoietic 
cells triggered missing-self reactivity. Surprisingly, down-regulation of MHC-I only on CD4+ T cells predominately induced 
tolerance to missing-self without resetting NK cell responsiveness. In this setting, inflammation triggered substantial 
missing-self reactivity. These results show that MHC-I down-regulation can induce either NK cell tolerance or killing in vivo 
and that inflammation promotes missing-self reactivity.
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Introduction
Natural killer (NK) cells are innate lymphoid cells that control 
viral infections and tumors through cytotoxicity and production 
of cytokines such as IFN-γ (Orr and Lanier, 2010). According to 
the “missing-self ” hypothesis, NK cells complement T cell im-
munity by killing infected and transformed cells that down-reg-
ulate MHC-I to evade MHC-I–restricted T cells (Kärre et al., 
1986). NK cells recognize MHC-I through germline-encoded 
MHC-I–specific inhibitory receptors, such as mouse Ly49 recep-
tors (Karlhofer et al., 1992) that prevent NK cell activation via 
cytoplasmic immunoreceptor tyrosine-based inhibitory motifs 
(Long et al., 2013). Loss of MHC-I, i.e., missing-self, relieves 
inhibitory signals, allowing NK cell activation; however, the re-
quirements for missing-self reactivity in vivo are incompletely 
understood. A better understanding of this process will inform 
efforts to improve cancer immunotherapies that use NK cells and 
missing-self recognition (Daher and Rezvani, 2018).
Evidence for the missing-self hypothesis comes from studies 
showing that NK cells kill MHC-I–deficient tumor cell lines and 
T cell blasts in vitro (Kärre et al., 1986; Höglund et al., 1991; Liao 
et al., 1991) and adoptively transferred MHC-I–deficient cells in 
vivo (Kärre et al., 1986; Bix et al., 1991). However, it has long been 
recognized that NK cells from MHC-I–deficient mice, such as 
mice that lack β2-microglobulin (B2m−/−), are not autoreactive 
as predicted by the missing-self hypothesis (Bix et al., 1991; Liao 
et al., 1991). In contrast, NK cells from B2m−/− mice are unable 
to reject MHC-I–deficient grafts in vivo (Bix et al., 1991) and ex-
hibit defective killing of MHC-I–deficient T cell blasts in vitro 
(Höglund et al., 1991; Liao et al., 1991). These results suggest that 
NK cells from MHC-I–deficient mice are tolerant to missing-self; 
however, the mechanisms that establish NK cell self-tolerance in 
MHC-I–deficient mice remain poorly understood.
Early studies proposed that NK cells maintain self-tolerance 
by expressing at least one MHC-I–specific inhibitory receptor 
that binds self-MHC-I (Valiante et al., 1997). Some NK cells in WT 
mice, however, can establish self-tolerance without expressing 
any known self-MHC-I–specific inhibitory receptors (Fernandez 
et al., 2005). Moreover, although the Ly49 repertoire is altered 
in MHC-I–deficient mice (Salcedo et al., 1997), the receptor rep-
ertoire model, based on known receptors, is unable to explain 
how NK cells establish self-tolerance in the absence of MHC-I. 
As a result, receptor repertoire development may contribute to 
NK cell self-tolerance, but it is likely that additional tolerance 
mechanisms exist.
More recent studies have suggested that NK cell self-tolerance 
is achieved through alterations in NK cell functionality rather 
than receptor repertoire (Fernandez et al., 2005; Kim et al., 
2005). NK cells from MHC-I–deficient mice are hyporesponsive 
to stimulation through antibody-mediated cross-linking of their 
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activation receptors (Fernandez et al., 2005; Kim et al., 2005). 
Additionally, NK cells from WT mice that lack self-MHC-I–
specific inhibitory receptors are similarly hyporesponsive 
(Fernandez et al., 2005; Kim et al., 2005). Also, inactivating mu-
tations in the immunoreceptor tyrosine-based inhibitory motifs 
of self-MHC-I–specific inhibitory Ly49 receptors render NK cells 
hyporesponsive (Kim et al., 2005; Bern et al., 2017). These results 
have been used to argue that self-MHC-I–specific inhibitory re-
ceptors “license” or “educate” NK cells to become responsive to 
triggering through their activation receptors (Kim et al., 2005). 
NK cells from MHC-I–deficient mice have thus been proposed 
to be self-tolerant because they are unlicensed or uneducated 
(Yokoyama and Kim, 2006); however, it is unclear if there are 
other contributors to NK cell tolerance.
Interestingly, NK cells can reset their educated phenotype to 
adapt to different MHC-I environments. Transfer of NK cells from 
MHC-I–deficient to –sufficient mice or up-regulation of MHC-I 
expression with an inducible MHC-I transgene improves NK cell 
responses to stimulation through activation receptors (Elliott et 
al., 2010; Joncker et al., 2010; Ebihara et al., 2013). In contrast, 
transfer of NK cells from WT to B2m−/− mice results in a loss of NK 
cell education (Joncker et al., 2010). Similarly, NK cells residing 
in MHC-I–deficient tumors adapt to the local MHC-I–deficient 
environment and become hyporesponsive (Ardolino et al., 2014). 
These results suggest that the educated NK cell phenotype is plas-
tic, allowing NK cells to adapt to changing MHC-I environments, 
but this has only been evaluated with adoptive transfer of NK cells. 
It then becomes unclear if loss of MHC-I expression in a previ-
ously MHC-I–positive environment with educated NK cells, i.e., 
“acute” MHC-I down-regulation, induces killing or NK cell adapta-
tion. As a result, it is not known when missing-self occurs in vivo.
NK cells from irradiation chimeras reconstituted with 1:1 mix-
tures of WT and B2m−/− fetal liver cells are tolerant of adoptively 
transferred MHC-I–deficient cells while remaining responsive to 
stimulation through their activation receptors (Wu and Raulet, 
1997; Shifrin et al., 2016). These results suggest that NK cells in 
mixed WT: B2m−/ − chimeras are tolerant to missing-self, perhaps 
in a manner related to the NK cell transfer and inducible MHC-I 
studies mentioned previously (Elliott et al., 2010; Joncker et 
al., 2010; Ebihara et al., 2013). Interestingly, tolerance to miss-
ing-self in chimeric mice is broken by infection with murine 
CMV (MCMV) or treatment with cytokines (Sun and Lanier, 
2008; Shifrin et al., 2016). However, it remains unknown if this 
form of tolerance is restricted to mixed chimeras in which NK 
cells are chronically exposed to missing-self targets or if it more 
generally applies to other settings. Additionally, it is unclear if 
inflammatory cytokines are required for missing-self recogni-
tion in general or if they are only required to break the form of 
tolerance that develops in mixed chimeras.
Here, we generated mice in which B2m could be inducibly de-
leted to directly study the response of NK cells that developed in 
an MHC-I–sufficient setting to acute down-regulation of MHC-I 
in vivo. MHC-I down-regulation was found to induce multiple 
NK cell responses besides missing-self reactivity that depended 
on the context. Importantly, the inflammatory environment in 
which MHC-I was down-regulated was found to regulate NK cell 
missing-self reactivity.
Results
Generation of conditional B2m knockout mice
To develop a mouse in which MHC-I expression could be 
down-regulated, we generated floxed B2m mice. C57BL/6 em-
bryonic stem (ES) cells were obtained with a B2m knockout 
first allele with conditional potential (B2mtm1a; Fig.  1  A). The 
HEPD0673_4_D09 ES cell clone was micro-injected into Albino 
B6 blastocysts so that germline transmission could be assessed 
by coat color. Mice containing the germline-transmitted B2mtm1a 
allele were confirmed by PCR and bred to a FLP deleter strain to 
remove the lacZ and neor genes flanked by FLT recognition target 
sites to generate the floxed B2m allele (B2mfl; Fig. S1, A–D).
To validate the B2mfl allele, floxed B2m mice were bred with 
CMV-Cre transgenic mice for ubiquitous expression of Cre to in-
duce germline deletion of B2m (B2mΔ; Fig. 1 A and Fig. S1, A–D). 
Splenocytes from B6 (WT) and B2mfl/fl mice both expressed sur-
face H-2Kb and H-2Db (Fig. 1 B). In contrast, the original germ-
line B2m knockout (B2m−/−) and the B2mΔ/Δ mouse both lacked 
surface expression of MHC-I (Fig. 1 B). In addition, B2mΔ/Δ mice 
were deficient in CD8+ T cells (Fig. 1, C and D), consistent with 
impaired positive selection of cytotoxic T cells as originally de-
scribed in B2m−/− mice (Koller et al., 1990; Zijlstra et al., 1990). 
Furthermore, splenocytes from B2mΔ/Δ mice were rejected after 
transfer into WT mice to a similar extent as B2m−/− splenocytes, 
and this rejection was abrogated by depletion of NK cells with 
the anti-NK1.1 antibody (Fig. 1, E and F), as previously described 
(Öberg et al., 2004). Collectively, these data indicate that B2mfl/fl 
mice express MHC-I and that Cre mediates B2m deletion, result-
ing in cells from B2mΔ/Δ mice that lack surface MHC-I and are 
targets for missing-self recognition.
NK cell missing-self reactivity is not observed after global 
down-regulation of MHC-I
To study the in vivo NK cell response to acute down-regulation 
of MHC-I, floxed B2m mice were bred to Rosa26-Cre-ERT2 (R26-
Cre-ERT2) mice that express a ubiquitous tamoxifen-inducible 
Cre. Tamoxifen treatment of B2mfl/fl R26-Cre-ERT2 mice induced 
genetic deletion of B2m as assessed by PCR (Fig. S1, E and F). We 
expected that tamoxifen treatment of B2mfl/fl R26-Cre-ERT2 mice 
would induce the accumulation of MHC-I–deficient cells only 
when NK cells were depleted. Surprisingly, tamoxifen induced 
the accumulation of a substantial population of MHC-I–defi-
cient cells in B2mfl/fl R26-Cre-ERT2 mice even in the presence of 
NK cells (Fig. 2, A and B). In addition, depletion of NK cells with 
the anti-NK1.1 antibody did not lead to any observed increase in 
MHC-I–deficient cells (Fig. 2, A and B). These data suggest that 
global down-regulation of MHC-I does not induce overt NK cell 
missing-self reactivity as predicted by the missing-self hypoth-
esis (Kärre et al., 1986).
To investigate the reasons why NK cell reactivity was not ob-
served after global down-regulation of MHC-I, we first used con-
ventional assays to test whether cells from B2mfl/fl R26-Cre-ERT2 
mice fail to become targets for missing-self recognition by NK 
cells after tamoxifen treatment (Fig. 2, C and D). B2mfl/fl, B2mfl/fl 
R26-Cre-ERT2, and B2mΔ/Δ mice were treated with either tamoxi-
fen or vehicle control (corn oil), and splenocytes from these mice 
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cific rejection was quantified by calculating the relative recovery 
of donor cell populations normalized to NK cell–depleted recip-
ient mice. Splenocytes from B2mfl/fl R26-Cre-ERT2 mice were re-
jected by NK cells only when the donor mice were treated with 
tamoxifen (Fig.  2, C and D). Control B2mfl/fl splenocytes were 
not rejected when donor mice received tamoxifen. In contrast, 
B2mΔ/Δ splenocytes were strongly rejected by NK cells, regardless 
of whether the donor mice received tamoxifen or corn oil. These 
data show that the MHC-I–deficient cells induced by tamoxifen 
in B2mfl/fl R26-Cre-ERT2 mice become targets for missing-self 
recognition by NK cells upon adoptive transfer. However, NK 
cells in tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice appear to 
remain tolerant to these potential missing-self targets.
NK cells adapt to global down-regulation of MHC-I
A previous attempt to generate a mouse with inducible deletion 
of an H-2Dd transgene driven by Mx1-Cre or CMV-Cre-ER was 
confounded by baseline leakiness of Cre expression that in-
duced NK cell tolerance to H-2Dd–deficient cells in the absence 
of tamoxifen (Ioannidis et al., 2001). To test if there was similar 
Figure 1. Conditional deletion of B2m leads to loss of surface MHC-I. (A) The targeted B2mtm1a allele is depicted before (top) and after (middle) removal 
of the LacZ and neomycin resistance (neor) genes by FLP recombinase. Germline-expressed Cre recombinase was used to generate the B2mΔ allele (bottom). 
(B) Representative histograms of H-2Kb and H-2Db expression on total lymphocytes from spleens of WT, B2mfl/fl, B2m−/−, and B2mΔ/Δ mice. (C) Representative 
dot plots showing the percentage of T cells (CD19− CD3+) that express CD4 or CD8. Data in B and C are representative of two independent experiments with 
three mice per group. (D) Total splenic CD8+ T cell number in WT, B2mfl/fl, B2m−/−, and B2mΔ/Δ mice (n = 6 mice per group). Data in D are combined from two 
independent experiments. (E and F) Splenocytes from WT, B2mfl/fl, B2m−/−, and B2mΔ/Δ mice were labeled with CFSE and differentially labeled with CT violet 
and CT far red as indicated. Labeled cells were injected i.v. into WT recipient mice, and donor cells were recovered from spleens of recipients after 2 d. (E) 
Representative dot plots showing the relative percentages of transferred cells (CFSE+) recovered from the spleens of WT recipient mice that were depleted of 
NK cells with anti-NK1.1 (right) or undepleted (middle). (F) Percentage of NK cell–specific rejection of donor cells by WT recipient mice (n = 4–5 recipient mice 
per group). Data in F are representative of two independent experiments with four to five recipient mice per group that received the same mix of donor cells in 
each experiment. Statistical significance was calculated by one-way ANO VA with Bonferroni’s multiple comparisons test. Each symbol in D and F represents 
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leakiness of Cre in our B2mfl/fl R26-Cre-ERT2 mice, we performed 
an in vivo cytotoxicity assay in B2mfl/fl and B2mfl/fl R26-Cre-ERT2 
mice that had been pretreated with vehicle control or tamoxifen 
(Fig. 3 A). NK cells from B2mfl/fl R26-Cre-ERT2 mice treated with 
vehicle control robustly rejected B2mΔ/Δ splenocytes, although to 
a slightly lower extent than NK cells from B2mfl/fl mice (Fig. 3, B 
and C). In contrast, NK cells from tamoxifen-treated B2mfl/fl R26-
Cre-ERT2 mice were unable to reject B2mΔ/Δ splenocytes (Fig. 3, B 
and C). These results demonstrate that NK cells from B2mfl/fl R26-
Cre-ERT2 mice are initially capable of rejecting MHC-I–deficient 
cells; however, induced global MHC-I down-regulation results in 
NK cell tolerance to missing-self.
Importantly, we did not observe any changes in NK cell num-
ber after global down-regulation of MHC-I in B2mfl/fl R26-Cre-
ERT2 mice (Fig. S2 A), and we observed only minor changes in NK 
cell maturation based on CD11b, CD27, and KLRG1 expression (Fig. 
S2, B and C). Additionally, the NK cell inhibitory receptor rep-
ertoire was relatively unchanged by global down-regulation of 
MHC-I besides subtle changes in expression of Ly49C, Ly49F, and 
Ly49G2 (Fig. S2 D). Thus, it seems unlikely that global down-reg-
ulation of MHC-I induces NK cell tolerance through impacting 
NK cell development or the receptor repertoire.
Previous adoptive transfer studies have shown that WT NK 
cells can reset their responsiveness to stimulation through ac-
tivation receptors when placed in an MHC-I–deficient environ-
ment (Joncker et al., 2010). To test if NK cells adapt to global loss 
of MHC-I, we treated B2mfl/fl and B2mfl/fl R26-Cre-ERT2 mice 
with tamoxifen or vehicle control and subsequently stimulated 
splenocytes with plate-bound anti-NK1.1 antibody as previously 
described (Kim et al., 2005; Jonsson and Yokoyama, 2010). IFN-γ 
production was analyzed as a measure of NK cell responsiveness, 
and an Ly49C licensing ratio was calculated to measure the pref-
erential capacity of Ly49C+ NK cells to respond to stimulation 
(see Materials and methods). As expected, only a small percent-
age of NK cells from B2mΔ/Δ mice produced IFN-γ after stimula-
tion (Fig. 3, D and E), which corresponded to an Ly49C licensing 
ratio <1 (Fig. 3, D and F). In contrast, a large fraction of control 
NK cells from B2mfl/fl mice produced IFN-γ after anti-NK1.1 stim-
Figure 2. Global down-regulation of MHC-I does not induce overt NK cell missing-self reactivity. (A) Representative histograms showing H-2Kb expres-
sion on CD45+ lymphocytes from peripheral blood of B2mfl/fl R26-Cre-ERT2 mice treated with tamoxifen starting on day 0. Mice were injected i.p. with anti-NK1.1 
antibody to deplete NK cells or with PBS control as indicated. (B) The percentage of H-2Kb–deficient CD45+ cells that accumulate in the blood of tamoxi-
fen-treated B2mfl/fl R26-Cre-ERT2 mice over time (n = 4 mice per group). Similar results to those in A and B were observed in a second experiment with three 
mice per group. (C and D) B2mfl/fl, B2mfl/fl R26-Cre-ERT2, and B2mΔ/Δ mice were treated with tamoxifen or vehicle control on days 0–4, and splenocytes were 
harvested and labeled with CFSE plus CT violet and CT far red as indicated on day 16. Labeled splenocytes were i.v. injected into WT recipients, and recovery 
of donor cells was analyzed after 2 d. (C) Representative dot plots showing the relative percentages of transferred cells (CFSE+) recovered from the spleens of 
WT recipient mice that were depleted of NK cells with anti-NK1.1 (right) or undepleted (left). (D) NK cell–specific rejection of the indicated donor cells combined 
from three independent experiments in which donor cells were injected on day 14 or 16 (each symbol represents an average of four to five recipient mice injected 
with the same mix of donor cells; two-way ANO VA with Bonferroni’s multiple comparisons test). CT far red labeling was inverted in one of the replicates in D. 
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ulation, regardless of whether or not the mouse was pretreated 
with tamoxifen (Fig. 3, D and E). Additionally, Ly49C+ NK cells 
from B2mfl/fl mice were preferentially responsive to stimulation 
through NK1.1, as indicated by an Ly49C licensing ratio >1 (Fig. 3, 
D and F). These baseline data show that NK cells from B2mΔ/Δ mice 
are unlicensed, while NK cells from B2mfl/fl mice are licensed as 
previously shown for B2m−/− and WT NK cells (Kim et al., 2005).
However, NK cells from tamoxifen-treated B2mfl/fl R26-Cre-
ERT2 mice exhibited reduced IFN-γ production in response to 
anti-NK1.1 stimulation (Fig. 3, D and E). Additionally, NK cells 
Figure 3. Global down-regulation of MHC-I induces loss of NK cell licensing. (A) B2mfl/fl and B2mfl/fl R26-Cre-ERT2 mice were treated with tamoxifen or 
vehicle control followed by i.v. injection of labeled donor splenocytes as indicated. (B) Representative histograms showing the relative percentages of trans-
ferred B2mfl/fl and B2mΔ/Δ cells (CFSE+ CT far redlow) recovered from the spleens of recipient mice after 2 d. B2mfl/fl and B2mΔ/Δ cells were differentially labeled 
with CT violet as indicated. (C) Summary of NK cell–specific rejection of B2mΔ/Δ donor cells (n = 4–5 mice per group; two-way ANO VA with Bonferroni’s multiple 
comparisons test). Data in C are combined from two independent experiments. Similar results were seen with WT and B2m−/− donor splenocytes (CFSE+ CT 
far redhigh) that were cotransferred in these experiments. (D–G) B2mfl/fl, B2mfl/fl R26-Cre-ERT2, and B2mΔ/Δ mice were treated with tamoxifen or vehicle control 
on days 0–4, and splenocytes were stimulated on day 14 with plate-bound anti-NK1.1 antibody or PMA and ionomycin. (D) Representative dot plots showing 
percentage of NK cells (CD3− CD19− NKp46+) that express Ly49C and IFN-γ after stimulation with plate-bound anti-NK1.1. (E) Percentage of NK cells that 
express IFN-γ after stimulation with plate-bound anti-NK1.1 (n = 3–4 mice per group; one-way ANO VA with Bonferroni’s multiple comparisons test). (F) Relative 
production of IFN-γ by Ly49C+ and Ly49C− NK cells after stimulation with anti-NK1.1 is quantified by an Ly49C licensing ratio (see Materials and methods; n = 
3–4 mice per group; one-way ANO VA with Bonferroni’s multiple comparisons test). (G) Percentage of NK cells that express IFN-γ after stimulation with PMA 
and ionomycin (n = 3–4 mice per group). Data in D–G are representative of two independent experiments with three to four mice per group. Each symbol in 
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from tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice exhibited 
an Ly49C licensing ratio <1 (Fig. 3, D and F). In contrast, control 
NK cells from B2mfl/fl R26-Cre-ERT2 mice pretreated with vehicle 
control produced IFN-γ at levels similar to B2mfl/fl mice. Impor-
tantly, NK cells from tamoxifen-treated B2mfl/fl R26-Cre-ERT2 
mice produced IFN-γ at levels similar to controls in response to 
stimulation with PMA and ionomycin, which bypasses activation 
receptor triggering (Fig. 3 G). These data indicate that NK cells 
remain capable of producing IFN-γ after global MHC-I down-reg-
ulation, but they become hyporesponsive to stimulation through 
activation receptors, i.e., they become unlicensed. Thus global 
down-regulation of MHC-I induces NK cell tolerance to miss-
ing-self through resetting NK cell education.
Missing-self is observed after down-regulation of MHC-I on a 
small population of cells
Early studies showed that NK cell–mediated rejection of hema-
topoietic grafts could be overcome by large doses of transferred 
cells (Cudkowicz and Bennett, 1971; Murphy et al., 1987; Koh et 
al., 2005). To test if the effect of MHC-I down-regulation depends 
on the number of missing-self targets, we generated mixed bone 
marrow (BM) chimeras with different ratios of donor BM to 
produce chimeric mice in which variable percentages of hema-
topoietic cells were reconstituted from B2mfl/fl R26-Cre-ERT2 BM 
(Fig. 4, A and B). Before tamoxifen treatment, we determined the 
degree of chimerism and found that tamoxifen induced a loss of 
B2mfl/fl R26-Cre-ERT2 hematopoietic cells that was abrogated by 
NK cell depletion (Fig. 4 B). However, this missing-self reactiv-
ity was overcome when the percentage of B2mfl/fl R26-Cre-ERT2 
hematopoietic cells was increased (Fig. 4 B). In contrast, B2mfl/fl 
R26-Cre-ERT2 hematopoietic cell frequencies remained rela-
tively constant in vehicle-treated chimeras (Fig. 4 B). These re-
sults suggest that MHC-I down-regulation results in missing-self 
reactivity when MHC-I deficiency extends only to a limited 
number of cells.
To test if tamoxifen was similarly sufficient to induce miss-
ing-self on a small population of transferred cells, we adoptively 
transferred splenocytes from B2mfl/fl R26-Cre-ERT2 mice into WT 
recipients that were subsequently treated with tamoxifen or ve-
hicle control (Fig. 4 C). Remarkably, tamoxifen treatment resulted 
in only a small population of H-2Kb–deficient transferred cells 
(Fig. 4, D and E). However, depletion of NK cells with anti-NK1.1 
dramatically increased the percentage of H-2Kb–deficient trans-
ferred cells (Fig. 4 D and E), indicating NK cell–mediated selec-
tion for residual MHC-I+ cells with tamoxifen treatment in mice 
not receiving anti-NK1.1 depletion. To further validate this inter-
pretation, we directly compared cotransferred B2mfl/fl R26-Cre-
ERT2 splenocytes and control B2mfl/fl splenocytes after tamoxifen 
treatment and found selective loss of B2mfl/fl R26-Cre-ERT2 sple-
nocytes that was abrogated with NK cell depletion (Fig. 4, F and 
G). These data indicate that down-regulation of MHC-I on trans-
ferred cells is sufficient to induce missing-self recognition by NK 
cells. Because tamoxifen did not induce overt NK cell reactivity in 
B2mfl/fl R26-Cre-ERT2 mice (Fig. 2, A and B), these results together 
indicate that MHC-I down-regulation is capable of inducing dis-
tinct NK cell responses, cytotoxicity, or adaptation that depends 
on the dose of missing-self targets.
To further investigate how NK cells respond to intermediate 
doses of missing-self targets, we bred B2mfl/fl mice to CD4-Cre-
ERT2 transgenic mice to facilitate tamoxifen-induced deletion 
only in CD4+ T cells (Aghajani et al., 2012). CD4+ T cells were cho-
sen as target cells for the following reasons: CD4+ T cells consti-
tute a substantially smaller cell population compared with those 
targeted by the R26-Cre-ERT2, CD4+ T cells have been suggested 
to be targets for NK cell cytotoxicity (Lu et al., 2007; Waggoner et 
al., 2012), and the CD4-Cre-ERT2 does not target NK cells (Fig. 5, A 
and B). Treatment of B2mfl/fl CD4-Cre-ERT2 mice with tamoxifen 
induced a subtle but reproducible reduction in the percentage of 
CD4+ T cells; however, we did not observe a statistically signif-
icant reduction in CD4+ T cell number compared with tamoxi-
fen-treated B2mfl/fl mice (Fig. 5, C–E). These results suggest that 
down-regulation of MHC-I on CD4+ T cells leads to low-level 
missing-self recognition, similar to what was observed when 
∼10% of hematopoietic cells down-regulated MHC-I in mixed 
BM chimeras (Fig. 4 B). However, the majority of CD4+ T cells 
that down-regulated H-2Kb in response to tamoxifen were not 
rejected by NK cells (Fig. 5, A–E), suggesting that NK cells estab-
lish tolerance to the remaining MHC-I–deficient CD4+ T cells. To 
test this idea, we assessed whether B2mfl/fl CD4-Cre-ERT2 mice 
pretreated with tamoxifen were capable of rejecting transferred 
B2mΔ/Δ cells. B2mfl/fl CD4-Cre-ERT2 mice treated with vehicle 
control were able to reject B2mΔ/Δ splenocytes to a similar degree 
as B2mfl/fl controls (Fig. 5, F and G), indicating that B2mfl/fl CD4-
Cre-ERT2 NK cells were not tolerant to missing-self at baseline. 
However, tamoxifen treatment abrogated the ability of NK cells 
in B2mfl/fl CD4-Cre-ERT2 mice to reject B2mΔ/Δ splenocytes (Fig. 5, 
F and G). These results show that down-regulation of MHC-I only 
on CD4+ T cells induces NK cell tolerance toward missing-self.
NK cell tolerance to MHC-I–deficient CD4+ T cells is not 
due to education
To further investigate the mechanism by which NK cells establish 
tolerance to MHC-I–deficient CD4+ T cells in tamoxifen-treated 
B2mfl/fl CD4-Cre-ERT2 mice, we stimulated splenocytes from B2mfl/fl, 
B2mfl/fl CD4-Cre-ERT2, and B2mΔ/Δ mice with plate-bound an-
ti-NK1.1. A higher percentage of NK cells from tamoxifen-treated 
B2mfl/fl CD4-Cre-ERT2 mice produced IFN-γ after anti-NK1.1 stim-
ulation, as compared with B2mΔ/Δ mice (Fig. 6, A and B). Impor-
tantly, NK cells from tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 
mice produced IFN-γ at similar levels to B2mfl/fl mice and vehicle 
controls. This was accompanied by an Ly49C licensing ratio >1 in 
tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice, indicating that NK 
cells remained licensed through Ly49C (Fig. 6 C). We did notice a 
subtle reduction in the Ly49C licensing ratio comparing vehicle- 
and tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice in some exper-
iments, but this is of unclear significance because the licensing 
ratio was still >1 (Fig. 6 C). Together, these data show that NK cells 
remain responsive to stimulation through activation receptors 
after down-regulation of MHC-I on CD4+ T cells. These results sug-
gest that MHC-I down-regulation on CD4+ T cells does not induce 
the same resetting of NK cell education that was seen after global 
down-regulation of MHC-I. This suggests that distinct mecha-
nisms establish NK cell tolerance to missing-self in B2mfl/fl R26-
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Figure 4. Down-regulation of MHC-I is sufficient for missing-self recognition of a limited number of cells. (A) Mixed BM chimeras were generated by 
reconstituting irradiated WT (CD45.1) mice with different ratios of BM from WT (CD45.1) and B2mfl/fl R26-Cre-ERT2 (CD45.2) mice. After 18–21 wk, chimeras 
were treated with tamoxifen or vehicle control starting on day 1, and peripheral blood was analyzed weekly from day 0 to 28. Chimeras were injected with 
anti-NK1.1 to deplete NK cells or with PBS on day −2 and every 7 d after. (B) Percentage of B2mfl/fl R26-Cre-ERT2 cells remaining in the blood on day 28 relative 
to day 0. Percentage of CD45.2+ cells was assessed within all CD45.1 and/or CD45.2+ lymphocytes. (C) Splenocytes from B2mfl/fl and B2mfl/fl R26-Cre-ERT2 
mice were labeled with CT far red and differentially labeled with CT violet and i.v. injected into WT recipient mice (20 × 106 of each donor). Recipient mice 
were subsequently treated with tamoxifen or vehicle for 5 d. Recipient mice were injected i.p. with anti-NK1.1 to deplete NK cells or with PBS control. (D) 
Representative histograms showing H-2Kb expression on transferred B2mfl/fl R26-Cre-ERT2 cells (CT far red+ CT violethigh) from blood of recipient mice over 
time. (E) Percentage of transferred B2mfl/fl R26-Cre-ERT2 cells that are H-2Kb–deficient in the blood of recipient mice over time (n = 6 mice per group; two-way 
repeated measure ANO VA with Bonferroni’s multiple comparisons test). Asterisks in E indicate statistical significance between the tamoxifen-treated groups 
treated with anti-NK1.1 or PBS. (F) Representative histograms showing the relative percentages of transferred cells (CT far red+) recovered from the spleens of 
recipient mice on day 14. B2mfl/fl (Cre−), and B2mfl/fl R26-Cre-ERT2 (Cre+) donor cells were distinguished by CT violet labeling as indicated. (G) Percentage of NK 
cell–specific rejection of B2mfl/fl R26-Cre-ERT2 donor cells by WT recipient mice treated as indicated (n = 6 mice per group; one-way ANO VA with Bonferroni’s 
multiple comparisons test). Data in B, E, and G are combined from two independent experiments in which all recipients within an experiment received the 
same mix of donor BM or splenocytes. Each symbol in B and G represents an individual recipient mouse. Error bars indicate mean ± SEM; *, P < 0.05; ****, P < 
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We next tested if NK cells from tamoxifen-treated B2mfl/fl 
CD4-Cre-ERT2 mice establish tolerance to MHC-I–deficient CD4+ 
T cells through skewing of the inhibitory receptor repertoire. We 
observed similar expression of Ly49 receptors and CD94/NKG2A 
on NK cells from tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice 
compared with vehicle-treated or B2mfl/fl mice (Fig. 6, D and E). 
Additionally, we did not observe any alterations in NK cell num-
ber or maturation based on expression of CD11b, CD27, and KLRG1 
in tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice (Fig. S3). Nota-
bly, we also did not detect up-regulation of the activation marker 
CD69 or markers of T cell exhaustion such as PD-1, LAG-3, TIM-
3, or CTLA-4 (Wherry and Kurachi, 2015) in response to MHC-I 
down-regulation on CD4+ T cells (Fig. S4 E). These data suggest 
that NK cell tolerance to missing-self after MHC-I down-regula-
tion on CD4+ T cells does not result from mechanisms analogous 
to T cell anergy, clonal deletion, or exhaustion, which render T 
cells hyporesponsive or alter the T cell receptor repertoire (Xing 
and Hogquist, 2012; Schietinger and Greenberg, 2014).
Figure 5. Minimal NK cell reactivity is observed after down-regulation of MHC-I on CD4+ T cells. B2mfl/fl and B2mfl/fl CD4-Cre-ERT2 mice were treated 
with tamoxifen or vehicle control on days 0–4, and spleens were harvested for flow cytometry on day 14. (A) Percentage of NK cells (CD45+ CD19− CD3− NK1.1+ 
NKp46+), B cells (CD45+ CD3− CD19+), CD8+ T cells (CD45+ CD19− CD3+ CD4− CD8+), and CD4+ T cells (CD45+ CD19− CD3+ CD8− CD4+) that express H-2Kb after 
treatment with tamoxifen (closed bars) or vehicle (open bars; n = 10 mice per group). (B) Representative histograms showing H-2Kb expression on the indicated 
cell types. (C) Representative dot plots showing the percentage of splenic T cells (CD45+ CD19− CD3+) that express CD4 or CD8. (D) Percentage of splenic T cells 
that express CD4 (n = 10 mice per group). (E) Number of CD4+ splenic T cells (n = 10 mice per group). Data in A, D, and E are combined from three independent 
experiments. (F and G) B2mfl/fl and B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen or vehicle control on days 0–4 followed by i.v. injection of labeled 
donor splenocytes on day 14. Recipient spleens were harvested after 2 d to analyze donor cell recovery. (F) Representative histograms showing the relative 
percentages of transferred cells (CFSE+) recovered from the spleens of recipient mice. (G) Summary of NK cell–specific rejection of B2mΔ/Δ donor cells (n = 4–6 
mice per group). Data in G is combined from two independent experiments in which all recipients within an experiment received the same mix of donor cells. 
Statistical significance was calculated by two-way ANO VA with Bonferroni’s multiple comparisons test. Each symbol in A, D, E, and G represents an individual 
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Figure 6. NK cell responsiveness and receptor repertoire are not affected by MHC-I down-regulation on CD4+ T cells. B2mfl/fl, B2mfl/fl CD4-Cre-ERT2, and 
B2mΔ/Δ mice were treated with tamoxifen or vehicle control on days 0–4, and splenocytes were harvested on day 14 for anti-NK1.1 stimulation and receptor 
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Robust missing-self reactivity occurs in the context  
of infection
Previous studies have shown that MCMV infection breaks NK 
cell tolerance to missing-self in mixed WT: B2m−/ − chimeras (Sun 
and Lanier, 2008; Shifrin et al., 2016). This led us to hypothesize 
that viral infection induces NK cell missing-self reactivity in re-
sponse to acute down-regulation of MHC-I as well. To test this 
idea, B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen and 
subsequently infected with Δm157 MCMV (Fig. 7 A). Mice were 
infected with Δm157 instead of WT MCMV to exclude the effects 
of Ly49H-mediated cytotoxicity and so that NK cells could be de-
pleted without significantly increasing the viral burden (Brown 
et al., 2001; Bubić et al., 2004; Parikh et al., 2015), which could 
have confounded previous experiments with mixed chimeras 
(Sun and Lanier, 2008). In the context of NK cell depletion, CD4+ 
T cells from tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice were 
mostly MHC-I deficient, even in the context of infection (Fig. 7 B). 
Remarkably, however, a high percentage of CD4+ T cells in un-
depleted B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen and 
infected with Δm157 MCMV expressed MHC-I (Fig. 7 B). This se-
lection for MHC-I–positive cells was accompanied by a reduction 
in the number of splenic CD4+ T cells in tamoxifen-treated B2mfl/fl 
CD4-Cre-ERT2 mice infected with Δm157 MCMV compared with 
NK cell–depleted mice and B2mfl/fl controls (Fig. 7 C). These results 
together suggest that in the context of Δm157 MCMV infection, 
NK cells robustly reject CD4+ T cells that down-regulate MHC-I.
Pattern recognition receptor agonist stimulation drives NK 
cell reactivity toward missing-self
Previous studies have shown that cytotoxic control of MCMV 
requires cytokine stimulation of NK cells to promote expres-
sion of perforin and granzyme B (Fehniger et al., 2007; Lucas 
et al., 2007; Parikh et al., 2015), but it is unclear if cytokines 
play a similar role in NK cell self-tolerance. We hypothesized 
that NK cell missing-self reactivity in tamoxifen-treated B2mfl/fl 
CD4-Cre-ERT2 mice during viral infection might be regulated 
by inflammatory cytokines instead of NK cell education. To 
test the role of inflammation in missing-self recognition in 
vivo, B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen 
followed by PBS or poly(I:C), an adjuvant that signals through 
the pattern recognition receptors (PRRs) TLR3 and MDA5 to 
induce production of inflammatory cytokines that activate NK 
cells (Akazawa et al., 2007; McCartney et al., 2009). Poly(I:C) 
thus mimics aspects of the inflammatory environment induced 
by MCMV infection, which also triggers MyD88-dependent re-
sponses (Krug et al., 2004). Remarkably, poly(I:C) induced rapid 
loss of CD4+ T cells from the peripheral blood of B2mfl/fl CD4-
Cre-ERT2, but not B2mfl/fl mice treated with tamoxifen (Fig.  7, 
D and E). This rapid loss of CD4+ T cells was not observed in 
B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen and PBS con-
trol (Fig.  7, D and E). Importantly, depletion of NK cells with 
anti-NK1.1 completely abrogated the loss of CD4+ T cells induced 
by poly(I:C) (Fig. 7, D and E). These data indicate that poly(I:C) 
induces NK cell missing-self reactivity in tamoxifen-treated 
B2mfl/fl CD4-Cre-ERT2 mice.
To test if poly(I:C) acts through potentiating missing-self 
recognition, expression of MHC-I was analyzed on residual 
CD4+ T cells from the spleens of B2mfl/fl CD4-Cre-ERT2 mice 
treated with tamoxifen and poly(I:C) (Fig. 7, F and G). Tamoxifen 
induced down-regulation of H-2Kb on ∼80% of splenic CD4+ T 
cells from B2mfl/fl CD4-Cre-ERT2 mice treated with PBS control. 
Remarkably, a substantially higher percentage of CD4+ T cells 
from B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen and 
poly(I:C) expressed H-2Kb compared with mice that did not re-
ceive poly(I:C) (Fig. 7, F and G). In contrast, depletion of NK cells 
with anti-NK1.1 completely abrogated this effect (Fig. 7, F and G), 
indicating that poly(I:C) induced an NK cell–dependent selection 
for MHC-I+ cells that was accompanied by an NK cell–dependent 
reduction in splenic CD4+ T cell number in B2mfl/fl CD4-Cre-ERT2 
mice treated with tamoxifen and poly(I:C) (Fig. 7 H). These data 
show that poly(I:C) induces NK cell reactivity toward MHC-I–de-
ficient CD4+ T cells, indicating that a PRR agonist can regulate NK 
cell reactivity toward missing-self.
To test if poly(I:C) promotes killing of MHC-I–deficient 
CD4+ T cells by affecting the NK cell or the target cell, short-
term killing of adoptively transferred B2mΔ/Δ CD4+ T cells 
was assessed using poly(I:C)-treated donor or recipient mice 
(Fig. S4, A and B). Subtle rejection of CD4+ T cells from PBS-
treated B2mΔ/Δ mice was observed during a 3-h in vivo cyto-
toxicity assay in PBS-treated recipient mice. CD4+ T cells from 
poly(I:C)-treated B2mΔ/Δ donor mice were rejected only slightly 
more than those from PBS-treated B2mΔ/Δ donors. In con-
trast, poly(I:C)-treated recipient mice exhibited substantially 
greater rejection of B2mΔ/Δ CD4+ T cells compared with PBS-
treated recipients (Fig. S4, A and B). Additionally, poly(I:C) was 
found to up-regulate granzyme B expression in NK cells from 
tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice (Fig. S4, C and 
D), similar to what has previously been shown in infected and 
poly(I:C)-treated WT mice (Fehniger et al., 2007; Lucas et al., 
2007; Parikh et al., 2015). Together, these results suggest that 
poly(I:C) promotes missing-self reactivity in tamoxifen-treated 
B2mfl/fl CD4-Cre-ERT2 mice at least in part by enhancing NK cell 
cytotoxic capacity.
IL-15–IL-15Rα-Fc complex promotes missing-self reactivity
Previous studies have suggested that NK cell expression of cy-
totoxic mediators during viral infection depends on trans-pre-
sentation of IL-15 (Fehniger et al., 2007; Lucas et al., 2007). To 
stimulation with plate-bound anti-NK1.1. (B) Summary of the percentage of total NK cells that express IFN-γ after stimulation with plate-bound anti-NK1.1 (n = 
3 mice per group; one-way ANO VA with Bonferroni’s multiple comparisons test). (C) The Ly49C licensing ratio for total NK cells after stimulation with anti-NK1.1 
(n = 3 mice per group; one-way ANO VA with Bonferroni’s multiple comparisons test). Data in B and C are representative of three independent experiments with 
three to four mice per group. (D) The percentage of NK cells (CD3− CD19− NK1.1+ NKp46+) that express the indicated receptor (n = 10 mice per group). Data in 
D are combined from three independent experiments. (E) Representative histograms showing expression of the indicated receptor on NK cells from B2mfl/fl 
and B2mfl/fl CD4-Cre-ERT2 mice treated with tamoxifen. Each symbol in B–D represents an individual mouse. Error bars indicate mean ± SEM; ** P < 0.01; *** 
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Figure 7. MCMV infection and poly(I:C) induce missing-self reactivity toward MHC-I–deficient CD4+ T cells. (A–C) B2mfl/fl and B2mfl/fl CD4-Cre-ERT2 
mice were treated with tamoxifen on days 0–4, injected with PBS or anti-NK1.1 antibody on day 9, and infected with 5 × 103 PFU of Δm157 MCMV on day 11. 
Splenocytes were harvested 4 d after infection for flow cytometry as depicted in A. Tam, tamoxifen; Veh, vehicle. (B) The percentage of CD4+ T cells (CD45+ 
CD19− CD3+ CD8− CD4+) that express H-2Kb in the spleens of mice 4 d after infection (n = 5–8 mice per group; two-way ANO VA with Bonferroni’s multiple 
comparisons test). (C) The number of splenic CD4+ T cells 4 d after infection (n = 5–8 mice per group; two-way ANO VA with Bonferroni’s multiple comparisons 
test). (D–H) B2mfl/fl and B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen on days 0–4, followed by i.p. injection of poly(I:C) or PBS on days 6, 9, and 
12. Mice were injected with anti-NK1.1 to deplete NK cells or with PBS control on day −2 and every 7 d after. (D) Representative dot plots showing CD4 and 
CD8 expression on peripheral blood T cells (CD45+ CD19− CD3+) on days 0 and 14. (E) Percentage of blood T cells that express CD4 over time (n = 4–7 mice 
per group). (F) Representative histogram showing H-2Kb expression on day 14 splenic CD4+ T cells from anti-NK1.1– or PBS-treated B2mfl/fl CD4-Cre-ERT2 
mice treated with tamoxifen and poly(I:C). (G) Percentage of splenic CD4+ T cells that express H-2Kb on day 14 (n = 4–9 mice per group; one-way ANO VA with 
Bonferroni’s multiple comparisons test). (H) Number of splenic CD4+ T cells on day 14 (n = 4–9 mice per group; one-way ANO VA with Bonferroni’s multiple 
comparisons test). Data in B, C, E, G, and H are combined from two independent experiments. Each symbol in B, C, G, and H represents an individual mouse. 
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test if IL-15 is sufficient to enhance NK cell missing-self reactiv-
ity, tamoxifen-treated B2mfl/fl CD4-Cre-ERT2 mice were treated 
with IL-15–IL-15Rα-Fc complex in a manner similar to previous 
studies (Rubinstein et al., 2006; Shifrin et al., 2016). IL-15–IL-
15Rα-Fc complex was found to induce a substantial reduction 
in CD4+ T cells that was abrogated by NK cell depletion (Fig. 8, 
A and B; and Fig. 8, D and E). Importantly, the residual CD4+ T 
cells in IL-15–IL-15Rα-Fc complex–treated B2mfl/fl CD4-Cre-ERT2 
mice were predominately H-2Kb+ unless mice were depleted of 
NK cells (Fig. 8 C; and Fig. 8, F and G). These results show that 
IL-15–IL-15Rα-Fc complex is sufficient to promote missing-self 
recognition of MHC-I–deficient CD4+ T cells by NK cells.
Discussion
Here, we show that down-regulation of MHC-I in vivo in a host 
that otherwise expressed MHC-I normally does not automat-
ically lead to NK cell–mediated rejection, as predicted by the 
missing-self hypothesis. Instead, while we acknowledge that 
the timing of MHC-I down-regulation induced by tamoxifen in 
our experiments appears not to be instantaneous, the “acute” or 
induced loss of MHC-I can result in multiple distinct NK cell re-
sponses. Global down-regulation of MHC-I was found to induce 
NK cell tolerance to missing-self by resetting NK cell education. 
In contrast, down-regulation of MHC-I on a fraction of hemato-
poietic cells in mixed BM chimeras, on transferred cells, or on 
CD4+ T cells could trigger missing-self recognition and cytotoxic-
ity. Additionally, CD4+ T cell–specific down-regulation of MHC-I 
was able to induce NK cell tolerance to missing-self without ev-
idence of an alteration in the capacity of NK cells to be triggered 
through their activation receptors. In this setting, viral infection, 
PRR agonist stimulation, and cytokine stimulation could drive 
robust NK cell reactivity toward missing-self. Thus, our find-
ings suggest that inflammation is important for breaking NK cell 
self-tolerance, despite the generally accepted paradigm based on 
the missing-self hypothesis alone.
The missing-self hypothesis predicts that down-regulation 
of MHC-I is sufficient to trigger NK cell cytotoxicity (Ljunggren 
and Kärre, 1990). In strong support of missing-self, host NK cells 
have been shown to kill adoptively transferred cells that were 
rendered MHC-I deficient by germline deletion of B2m (Bix et 
al., 1991), which was recapitulated here when MHC-I deficiency 
Figure 8. IL-15 agonist induces missing-self reactivity toward MHC-I–deficient CD4+ T cells. B2mfl/fl CD4-Cre-ERT2 mice were treated with tamoxifen on 
days 0–4 and i.p. injected with IL-15 + IL-15Rα-Fc (0.6 µg + 3 µg) on days 6, 8, and 10. Mice were injected with anti-NK1.1 or PBS on days 4, 5, and 12. (A) Repre-
sentative dot plots showing CD4 and CD8 expression on CD45+ blood lymphocytes. (B) Percentage of CD45+ blood lymphocytes that express CD4 over time. 
(C) Percentage of blood CD4+ T cells (CD45+ CD8− CD4+) that express H-2Kb over time. (D) Representative dot plot showing CD4 and CD8 expression by day 
14 spleen T cells (CD45+ CD19− NK1.1− CD1d-Tet− CD3+). (E) Number of splenic CD4+ T cells on day 14. (F) Representative histogram showing H-2Kb expression 
on day 14 splenic CD4+ T cells. (G) Percentage of splenic CD4+ T cells that express H-2Kb on day 14. Data in B, C, E, and G are combined from two independent 
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was induced on transferred splenocytes. In contrast, adoptive 
transfer of WT NK cells into MHC-I–deficient mice induced NK 
cells to adapt and become tolerant to missing-self (Joncker et al., 
2010). These functionally opposing outcomes raise the question: 
When does missing-self attack occur versus when does NK cell 
tolerance to missing-self occur instead? Our results show that 
acute down-regulation of MHC-I in vivo can induce both NK cell 
killing and tolerance in different contexts.
Acute down-regulation of MHC-I in mixed BM chimeras and 
on CD4+ T cells was sufficient to induce missing-self recognition 
and killing, but this appeared to be limited to only a small num-
ber of MHC-I–deficient cells. In contrast, we did not find any 
evidence for MHC-I–deficient cell depletion when we induced 
ubiquitous down-regulation of MHC-I. These results could be 
due to enhanced susceptibility of certain cell types to NK cell lysis 
compared with others. Alternatively, it is possible that we did not 
observe missing-self reactivity after global MHC-I down-regu-
lation because NK cells became overwhelmed or exhausted by 
the large dose of missing-self targets. However, NK cells did not 
appear to be hyporesponsive to activation stimuli after MHC-I 
down-regulation on CD4+ T cells. Additionally, NK cells did not 
up-regulate markers of T cell exhaustion (Wherry and Kurachi, 
2015) after down-regulation of MHC-I on CD4+ T cells. As a re-
sult, we favor the explanation that NK cells respond differently 
to missing-self depending on the dose of MHC-I–deficient cells. 
This is also supported by differences in NK cell activation re-
ceptor responses after down-regulation of MHC-I on all cells 
compared with only CD4+ T cells. In any case, an inflammatory 
environment, such as that induced by systemic MCMV infection, 
PRR agonist (poly[I:C]) administration, or simply cytokine (IL-
15–IL-15Rα-Fc complex) treatment, promoted NK cell cytotoxic-
ity toward most MHC-I–deficient CD4+ T cells. This mechanism 
ensures that robust NK cell killing of MHC-I–deficient “self ” 
cells primarily occurs in an inflammatory environment such as 
during an infection.
Our laboratory previously proposed that NK cell self-toler-
ance is established through a licensing (education) process that 
ensures that only NK cells that express self-MHC-I–specific in-
hibitory receptors become fully functional and capable of killing 
through missing-self recognition (Kim et al., 2005). As a result, 
we proposed that NK cells from B2m−/− mice were self-tolerant 
because they were unlicensed and hypofunctional, rather than 
because of changes in inhibitory receptor expression (Yokoyama 
and Kim, 2006). If licensing fully explains NK cell self-tolerance 
in B2m−/− mice, however, then acute down-regulation of MHC-I 
in a mouse that contains licensed NK cells should induce NK cell 
missing-self reactivity. In contrast, we found here that NK cells 
remained self-tolerant after global down-regulation of MHC-I 
in B2mfl/fl R26-Cre-ERT2 mice. Global down-regulation of MHC-I 
was found to only induce subtle changes in NK cell inhibitory 
receptor expression, which suggests that self-tolerance was not 
maintained through receptor repertoire skewing. In contrast, 
global down-regulation of MHC-I was found to “unlicense” NK 
cells, which presumably contributed to maintenance of self-tol-
erance. Surprisingly, down-regulation of MHC-I only on CD4+ T 
cells induced a slight loss of target cells, but NK cells did not alter 
their education and remained predominately self-tolerant in this 
setting as well. These data suggest that other mechanisms besides 
receptor repertoire skewing and NK cell education may contrib-
ute to NK cell tolerance to missing-self in settings where NK cells 
are exposed to missing-self targets but remain educated, similar 
to what has been suggested with mixed chimeras (Shifrin et al., 
2016). Notably, this form of NK cell self-tolerance was readily 
broken by inflammatory stimuli in B2mfl/fl CD4-Cre-ERT2 mice. 
These results suggest that a lack of inflammation at steady-state 
contributes to NK cell self-tolerance in B2m−/− mice in addition 
to the lack of NK cell education.
Previous studies have used adoptive transfer of WT NK cells 
into B2m−/− mice to suggest that NK cells adapt to changing 
MHC-I environments by resetting their education (Joncker et 
al., 2010). However, these studies were limited because MHC-I 
expression was only altered globally with the host B2m−/− mouse, 
which differs from settings of infection and tumorigenesis in 
which MHC-I down-regulation occurs on only a subpopulation 
of cells. Additionally, previous studies have suggested that T cells 
from B2m−/− mice can reject WT cells (Zijlstra et al., 1992; Apasov 
and Sitkovsky, 1993; Glas et al., 1994), which necessitated irradia-
tion or T cell depletion of recipient mice in these transfer exper-
iments (Joncker et al., 2010), which could have influenced the 
results. Here, we used the B2mfl/fl R26-Cre-ERT2 mouse to glob-
ally down-regulate MHC-I without impairing T cell development. 
Our results show that global down-regulation of MHC-I leads to 
loss of NK cell education, which is in agreement with prior adop-
tive transfer experiments (Joncker et al., 2010). Notably, it is un-
clear if NK cells become uneducated in response to global MHC-I 
down-regulation because they become over-activated and aner-
gic or because of a reeducation process that is independent of ac-
tivation signals. Surprisingly, down-regulation of MHC-I only on 
CD4+ T cells did not induce a loss of NK cell education. Our results 
may suggest that the dose of the MHC-I–deficient cells influences 
whether MHC-I down-regulation induces loss of NK cell educa-
tion or not. Alternatively, MHC-I expression by only specific cell 
types may be required to educate NK cells. Breeding the floxed 
B2m mouse to strains that express cell type–specific Cre will be 
valuable for distinguishing between these possibilities and for 
identifying specific cell types required to educate NK cells.
Previous studies using transgenic mice with mosaic H-2Dd 
expression (Johansson et al., 1997) and WT: B2m−/ − mixed fetal 
liver chimeras (Wu and Raulet, 1997) have suggested that chronic 
exposure to MHC-I–deficient cells dominantly induces toler-
ance to missing-self. Our results show that tamoxifen treatment 
of B2mfl/fl R26-Cre-ERT2 and B2mfl/fl CD4-Cre-ERT2 mice also 
induces tolerance to adoptively transferred MHC-I–deficient 
targets. However, acute down-regulation of MHC-I on a small 
percentage of cells in mixed BM chimeras led to missing-self re-
activity. These results extend previous findings by showing that 
acute down-regulation of MHC-I can also dominantly induce tol-
erance to missing-self, though we further show that this toler-
ance, at least in the acute setting, is dependent on the percentage 
of MHC-I–deficient cells in the host.
Because cytokines are known to stimulate NK cells to ex-
press perforin and granzyme B for cytotoxic control of MCMV 
(Fehniger et al., 2007; Parikh et al., 2015), we hypothesize that 








niversity In St. Louis Libraries user on 27 D
ecem
ber 2019
Bern et al. 
Inducible MHC-I deficiency and missing-self
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20181076
112
cytotoxic capacity of NK cells. Consistent with this idea, we 
observed that poly(I:C) induced elevated granzyme B expres-
sion in NK cells from mice with MHC-I–deficient CD4+ T cells. 
However, future studies with B2mfl/fl CD4-Cre-ERT2 mice bred to 
Gzmb−/− mice will be required to definitively determine the role 
of cytotoxic mediators in inflammation-induced missing-self 
recognition of MHC-I–deficient CD4+ T cells. Moreover, future 
studies will be needed to determine whether inflammation in-
duces missing-self reactivity through additional mechanisms, 
as well as through effects of inflammation on NK cell number, 
trafficking, and receptor repertoire and through effects of in-
flammation on other cell types. This NK cell tolerance to miss-
ing-self in B2mfl/fl CD4-Cre-ERT2 mice that can be broken by 
inflammation resembles T cell immunological ignorance, in 
which potentially autoreactive T cells are prevented from caus-
ing overt autoimmunity likely due in part to a lack of appropriate 
activation signals, rather than anergy or clonal deletion (Ohashi 
et al., 1991; Oldstone et al., 1991). Notably, the dose of self-antigen 
is thought to determine whether potentially autoreactive T cells 
remain ignorant or become tolerant (Kurts et al., 1999). Similarly, 
our results point to a role for the dose of MHC-I–deficient cells 
in determining whether NK cells ignore missing-self targets or 
adapt to them by becoming uneducated.
If cytokine stimulation is required for NK cells to kill MHC-I–
deficient targets, however, it still remains unclear how NK cells 
are capable of rejecting MHC-I–deficient transferred cells with-
out an inflammatory stimulus (Öberg et al., 2004). It is possi-
ble that the process of harvesting single cell suspensions from 
MHC-I–deficient mice induces stress signals and dead cells that 
trigger low-level inflammation in recipient mice. However, miss-
ing-self reactivity was also observed toward a small number of 
cells in mixed BM chimeras that were performed months after 
the BM transfer. Alternatively, perhaps basal levels of inflamma-
tion are sufficient to stimulate NK cells to kill a small number of 
missing-self targets. Intriguingly, IFN AR1−/− and IFN AR2−/− mice 
have been shown to be susceptible to MHC-I–deficient RMA/s 
tumors, suggesting that cytokine stimulation is essential for NK 
cell–mediated control of classical missing-self tumors (Swann 
et al., 2007). Additionally, it has long been acknowledged that in 
vitro NK cell cytotoxicity of MHC-I–deficient targets requires 
pretreating mice with poly(I:C) (Djeu et al., 1979; Liao et al., 1991) 
or activating NK cells in culture with cytokines such as IL-2 
(Grimm et al., 1982; Rosenstein et al., 1984). Collectively with 
our results, it seems likely that cytokine signaling in NK cells is 
generally required for missing-self reactivity; however, future 
studies will be needed to test if NK cells respond directly or indi-
rectly to specific cytokines to kill nontransformed cells that are 
rendered acutely MHC-I–deficient in vivo, as in our studies.
Previous studies with WT: B2m−/ − mixed chimeras have sug-
gested that infection or inflammation can break NK cell tolerance 
to missing-self (Sun and Lanier, 2008; Shifrin et al., 2016). It is 
unclear from these studies, however, if NK cells start out tolerant 
to missing-self in these chimeras, because in one study (Sun and 
Lanier, 2008), B2m−/− cells were gradually lost from the chimeras 
over time, and in a second study (Shifrin et al., 2016), B2m−/− cells 
were found to be stable in the chimeras. Additionally, it is unclear 
if this presumed tolerance to missing-self is unique to settings 
in which NK cells are chronically exposed to MHC-I–deficient 
cells or if it applies to settings in which MHC-I is down-regu-
lated acutely. Here we show that NK cells can remain tolerant to 
missing-self in response to acute MHC-I down-regulation. Ad-
ditionally, our results extend the previous findings from mixed 
chimeras by showing that inflammation plays a critical role in 
triggering NK cell missing-self reactivity toward self cells that 
acutely down-regulate MHC-I.
MHC-I–specific inhibitory receptors on NK cells are an ap-
pealing target for tumor immunotherapy; however, recent 
clinical trials failed to show efficacy of anti-KIR2D checkpoint 
blockade in patients with smoldering multiple myeloma (Korde 
et al., 2014). Antibody blockade of MHC-I–specific inhibitory re-
ceptors is predicted to induce NK cell missing-self recognition 
by mimicking the effects of MHC-I down-regulation. Our results, 
however, show that down-regulation of MHC-I alone does not 
induce substantial missing-self reactivity in vivo. In contrast, 
MHC-I down-regulation has the potential to induce NK cell tol-
erance through loss of education, which has been proposed to 
explain in part the lack of efficacy of anti-KIR2D checkpoint 
blockade (Carlsten et al., 2016). Notably, our results suggest that 
inflammation is needed to observe substantial NK cell reactiv-
ity toward missing-self targets in vivo. These results suggest 
that combination therapy with anti-KIR2D and an inflammatory 
stimulus or IL-15 agonist (Romee et al., 2018) may improve the ef-
ficacy of checkpoint blockade of NK cells as others have proposed 
previously (Vahlne et al., 2010; Ardolino et al., 2014), but also 
suggest that these combination therapies may have the potential 
to induce side-effects from NK cell–mediated autoreactivity.
Materials and methods
Mice
C57BL/6 (B6) and B6-Ly5.1 (B6.SJL-PtprcaPepcb/BoyCrCrl) 
mice were purchased from Charles River Laboratories. B2m−/− 
(B6.129P2-B2mtm1Unc/J), Albino B6 (B6(Cg)-Tyrc-2J/J), R26-Cre-
ERT2 (B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J), and CD4-Cre-ERT2 
(B6(129X1)-Tg(Cd4-cre/ERT2)11Gnri/J) mice were purchased 
from The Jackson Laboratory. FLP transgenic mice (C57BL/6-Tg - 
(CAG GS-Flpe)2ARTE) were purchased from Artemis Pharmaceu-
ticals. CMV-Cre mice (Schwenk et al., 1995) on the B6 background 
were provided by Marco Colonna (Washington University in St. 
Louis, St. Louis, MO). Control B2m−/− mice used in experiments 
were obtained from The Jackson Laboratory, either directly or 
subsequently bred in-house. B6 and B6-Ly5.1 mice used in exper-
iments were obtained directly from Charles River Laboratories. 
All other experimental and control mice were bred in-house at 
Washington University in St. Louis. Mice were 8–14-wk old at the 
start of experiments unless otherwise stated. Male and/or female 
mice were used in individual experiments without blinding or 
randomization. Animal protocols were approved by the Institu-
tional Animal Care and Use Committee at Washington Univer-
sity in St. Louis.
Development of floxed B2m mice
Three JM8A3.N1 (C57BL/6N-Atm1Brd) ES cell clones (HEPD0673_4_
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targeted allele B2mtm1a(EUC OMM)Hmgu (B2mtm1a) were purchased 
from the European Conditional Mouse Mutagenesis Consor-
tium (EUC OMM). Clone HEPD0673_4_D09 was confirmed to be 
correctly targeted by Southern blot analysis and was micro-in-
jected into Albino B6 blastocysts by the Transgenic, Knockout, 
and Micro-Injection Core at Washington University in St. Louis. 
Chimeric mice were bred to Albino B6 to identify germline trans-
mission by coat color. Mice containing the germline-transmitted 
B2mtm1a allele were subsequently bred to FLP transgenic mice to 
generate the B2mtm1c (B2mfl) allele. The albino and FLP alleles 
were removed through breeding. Mice carrying the B2mfl allele 
were bred to CMV-Cre transgenic mice to generate the B2mtm1d 
(B2mΔ) allele with a germline deletion of B2m. The CMV-Cre 
transgene was subsequently bred out before experiments with 
B2mΔ/Δ mice, except in one replicate of the experiment in Fig. 1 
(E and F), in which the B2mΔ/Δ donor cells were heterozygous for 
CMV-Cre. Excision by FLP and CMV-Cre were confirmed by PCR 
(Fig. S1, A–D) with Phusion High-Fidelity PCR Master Mix (New 
England Biolabs) with the following primers: primer a (5′-CAG 
CTC TCA GCA CTG GAT CA-3′), primer b (5′-GAA CTT CGG AAT AGG 
AAC TTCG-3′), primer c (5′-CAC CGT GCA CCA TCT TAC AT-3′), and 
primer d (5′-AGA GCC CTC ACC ACT TCT CA-3′). Genomic DNA was 
isolated from mice of varied ages for PCR in Fig. S1 (B–D).
Antibodies and flow cytometry
The following were purchased from BD Biosciences: anti-Ly49G2 
(4D11), anti-Ly49F (HBF-719), and streptavidin PE. The fol-
lowing were purchased from eBioscience: Fixable Viability 
Dye eFluor 506, Fixable Viability Dye eFluor 780, anti–IFN-γ 
(XMG1.2), anti-NKp46 (29A1.4), anti-NK1.1 (PK136), anti-CD19 
(eBio1D3), anti-CD3e (145-2C11), anti-CD11b (M1/70), anti-CD45 
(30-F11), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD4 (RM4-
5), anti-CD8b (eBioH35-17.2), anti-CD8a (53–6.7), anti–CTLA-4 
(UC10-4B9), anti–LAG-3 (eBioC9B7W), anti-Ly49H (3D10), an-
ti-Ly49E/F (CM4), anti–TIM-3 (RMT3-23), anti-Ly49D (eBio4E5), 
anti-CD69 (H1.2F3), anti-Ly49G2 (eBio4D11), anti-NKG2AB6 
(16a11), anti-CD94 (18d3), and anti-CD27 (LG.7F9). The following 
were purchased from BioLegend: streptavidin APC, anti-KLRG1 
(2F1), anti–PD-1 (29F.1A12), anti-NK1.1 (PK136), anti–H-2Kb (AF6-
88.5), and anti–H-2Db (KH95). The following was purchased from 
Abcam: anti-Ly49I (YLI-90). The following was purchased from 
Thermo Fisher: anti-Ly49F (HBF-719). The following was pur-
chased from Jackson ImmunoResearch: Alexa Fluor 647–conju-
gated Goat anti-Mouse IgG-γ, Fc subclass 3 specific (anti-mouse 
IgG3). PBS-57–loaded mouse CD1d tetramer (CD1d-tet) conju-
gated to PE was obtained from the National Institutes of Health 
Tetramer Core Facility. PK136 antibody (anti-NK1.1) was purified 
in our laboratory from supernatants of the PK136 hybridoma 
(American Type Culture Collection) or purchased from Leinco 
Technologies. NK cell depletion was performed by i.p. injection 
of 200 µg of purified PK136 antibody. Mice were excluded from 
analysis if PK136 injection was shown to be unsuccessful by flow 
cytometry for NK cells in the blood after the first injection or in 
the spleen. JR9 antibody (anti-Ly49A) was purified in our labora-
tory from supernatants of the JR9 hybridoma that was provided 
by Jacques Roland (Pasteur Institute, Paris, France). 4LO3311 
antibody (anti-Ly49C) was purified in our laboratory from su-
pernatants of the 4LO3311 hybridoma that was provided by Su-
zanne Lemieux (Institut National de la Recherche Scientifique, 
Institut Armand-Frappier, Laval, Quebec, Canada). Anti-Ly49A 
and anti-Ly49C antibodies were conjugated in our laboratory 
to FITC or to biotin using the EZ-Link Sulfo-NHS-LC-LC-biotin 
kit (Thermo Fisher). Ly49C staining was performed with either 
anti–Ly49C-biotin followed by fluorophore-conjugated strepta-
vidin or purified anti-Ly49C followed by anti-mouse IgG3–Alexa 
Fluor 647. Blocking of Fc receptors was performed with superna-
tants of the 2.4G2 (anti–Fc-γRII/III) hybridoma (American Type 
Culture Collection). Surface staining for flow cytometry was per-
formed on ice in either 2.4G2 supernatant or staining buffer (PBS 
with 1% BSA and 0.01% Sodium Azide). Cells were gated on lym-
phocytes with exclusion of doublets and exclusion of dead cells 
with Fixable Viability Dye (BD Biosciences) or forward scatter 
and side scatter (only in some in vivo cytotoxicity experiments). 
CD45+ cells throughout the text refers to cells stained with either 
the anti-CD45 or anti-CD45.2 antibody. CD8+ cells throughout the 
text refers to cells stained with either the anti-CD8a or anti-CD8b 
antibodies. Samples were analyzed using a FAC SCanto (BD Bio-
sciences) or a FAC SAria Fusion (BD Biosciences). Data were ana-
lyzed using FlowJo v9.9.6 or v10.4.2 (Tree Star).
Tamoxifen treatment of mice
Mice were administered tamoxifen (Sigma-Aldrich) by oral ga-
vage (4 mg/d for five consecutive days) in 200 µl of corn oil (Sig-
ma-Aldrich) as according to published protocols (Anastassiadis 
et al., 2010). In most experiments, NK cells were depleted from 
a subset of mice by i.p. injection of 200 µg anti-NK1.1 (PK136) 
antibody on day −2 and every 7 d after for the duration of the 
experiment unless stated otherwise. When indicated, 100 µg of 
poly(I:C) high molecular weight (InvivoGen) in 0.9% NaCl or a 
PBS control was administered to mice by i.p. injection.
In vivo cytotoxicity assay
Mice used for donor splenocytes in in vivo cytotoxicity assays were 
8–18 wk old at the time of transfer. Donor splenocytes were har-
vested and labeled in vitro with different combinations of CFSE 
(Life Technologies), CellTrace violet (CT violet; Thermo Fisher), 
and CT far red (Thermo Fisher). For experiments with six donor 
cell populations, all donor cells were labeled with 2.5 µM CFSE, 
and donors were differentially labeled with CT violet (5, 1, or 
0.2 µM) and CT far red (1 or 0.04 µM). For experiments with four 
donor cell populations, all donor cells were labeled with 2.5 µM 
CFSE, and donors were differentially labeled with CT violet (5 or 
0.2 µM) and CT far red (1 or 0.04 µM). For experiments with three 
donor cell populations, all donor cells were labeled with 2.5 µM 
CFSE, and donors were differentially labeled with CT violet (5 µM, 
1 µM, or 0.2 µM). For experiments with two donor cell populations, 
all donor cells were labeled with either 2.5 µM CFSE or with 0.2 µM 
CT far red, depending on the experiment. The two donor cell popu-
lations were differentially labeled with CT violet (5 or 0.2 µM). In 
some experiments, four donor cell populations were injected, but 
only two were displayed in the figure for clarity. Recipient mice 
were injected i.v. with 2 × 106 of each donor cell except for Fig. 4 
(D–G), in which 20 × 106 of each donor cell was injected. Spleens 








niversity In St. Louis Libraries user on 27 D
ecem
ber 2019
Bern et al. 
Inducible MHC-I deficiency and missing-self
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20181076
114
cells except for Fig. 4 (D–G) and Fig. S4 (A and B). NK cell–specific 
rejection was calculated by gating on transferred cells and exclud-
ing dead cells either by Fixable Viability Dye (BD Biosciences) or 
forward scatter and side scatter. Rejection was quantified as %Re-
jection = [1 − (Target/Control)/(Target/Control)Average(NK depleted)] × 
100, where the target was the donor cell of interest, and the control 
was a WT or B2mfl/fl donor cell population depending on the exper-
iment. In Fig. 2 D, %Rejection was calculated using vehicle-treated 
B2mfl/fl donor cells as the control. The ratio of target to control cells 
was normalized to the average ratio recovered from NK cell–de-
pleted mice to calculate rejection by NK cells.
In vitro splenocyte stimulations
Splenocytes were stimulated in vitro as previously described 
(Kim et al., 2005; Jonsson and Yokoyama, 2010). In brief, 5 × 
106 splenocytes in R10 media were plated into 24-well culture 
plates that that were precoated with anti-NK1.1 (PK136; 1 µg/
ml) or that contained 0.5 µg/ml PMA (Sigma-Aldrich) and 4 
µg/ml ionomycin (Sigma-Aldrich). Cells were incubated for a 
total of 7 h at 37°C. GolgiPlug (BD Biosciences) was added to the 
wells after the first hour. After stimulation, cells were stained 
with fixable viability dye and subsequently with antibodies 
to surface antigens. Cells were then fixed and permeabilized 
using the Fixation/Permeabilization Solution kit (BD Cytofix/
Cytoperm) to stain for intracellular IFN-γ. Fixable viability dye 
was used to gate on viable cells in all experiments. The Ly49C li-
censing ratio was calculated as follows (Jonsson and Yokoyama, 
2010): Ly49C licensing ratio = [(%Ly49C+IFN-γ+)/(%Ly49C+)]/
[(%Ly49C−IFN-γ+)/(%Ly49C−)].
MCMV infections
Infections were performed with 5 × 103 PFU of Δm157 MCMV, 
which was previously shown to differ from the WT1 MCMV strain 
by a single nucleotide (Cheng et al., 2010; Parikh et al., 2015). 
Mice were infected by i.p. injection of salivary gland propagated 
virus in 200 µl PBS.
Cytokine treatments
Murine IL-15 was purchased from PeproTech. Mouse IL-15R α Fc 
chimera protein (IL-15Rα-Fc) was purchased from R&D Systems. 
IL-15 and IL-15Rα-Fc were complexed by incubating a mixture of 
6.67 µg/ml IL-15 and 33.3 µg/ml IL-15Rα-Fc in PBS for 30 min at 
37°C before injection. Mice were injected i.p. with 0.6 µg IL-15 
and 3 µg IL-15Rα-Fc in 200 µl PBS every other day for a total of 
three injections. This dose of IL-15–IL-15Rα-Fc was chosen based 
on previous studies (Rubinstein et al., 2006; Shifrin et al., 2016). 
After IL-15–IL-15Rα-Fc complex treatment, splenic CD4+ T cells 
were gated as CD45+ CD19− NK1.1− CD1d-Tet− CD3+ CD8− CD4+ to 
exclude NKT cells because NKT cells have been shown to robustly 
expand in response to IL-15–IL-15Rα-Fc complex (Stoklasek et al., 
2006; Guo et al., 2015) and because MHC-I down-regulation was 
inefficient in CD4+ NKT cells in both PBS-treated and anti-NK1.1–
treated groups in these experiments (data not shown).
Mixed BM chimeras
B6-Ly5.1 mice were irradiated with 950 rad by either an x-ray or 
gamma irradiator. Irradiated mice were injected i.v. with mix-
tures of BM from WT B6-Ly5.1 (CD45.1) and B2mfl/fl R26-Cre-ERT2 
(CD45.2) mice. BM mixtures contained 0.5, 1, 5, 25, and 50% BM from 
B2mfl/fl R26-Cre-ERT2 mice. Chimeras were given antibiotic (sul-
famethoxazole/trimethoprim) water for ∼1 mo after irradiation. 
Experiments on mixed BM chimeras started 18–21 wk after recon-
stitution. Blood was collected weekly for 4 wk to assess chimerism, 
but data are shown only for the final day (day 28) for simplicity. The 
percentage of B2mfl/fl R26-Cre-ERT2 (CD45.2) cells remaining on 
day 28 is calculated as %Remaining = [(%CD45.2+/%CD45.1+)Day28/
(%CD45.2+/%CD45.1+)Day0] × 100. Chimerism was assessed within 
Live CD45.1 and/or CD45.2+ lymphocytes.
Statistics
Statistical analysis was performed using Prism 7 (GraphPad). P 
values were calculated using one-way ANO VA with Bonferroni’s 
multiple comparisons test, two-way ANO VA with Bonferroni’s 
multiple comparisons test, or unpaired t test. Asterisks indicate 
statistical significance as follows: ****, P < 0.0001; ***, P < 0.001; 
**, P < 0.01; *, P < 0.05; ns, not significant.
Online supplemental material
Fig. S1 shows genetic deletion with PCR within the B2m gene in 
B2mΔ/Δ and tamoxifen-treated B2mfl/fl R26-Cre-ERT2 mice. Fig. S2 
shows NK cell number, maturation, and receptor repertoire in 
B2mfl/fl R26-Cre-ERT2 mice treated with vehicle or tamoxifen. Fig. 
S3 shows NK cell number and maturation in B2mfl/fl CD4-Cre-
ERT2 mice treated with vehicle or tamoxifen. Fig. S4 shows that 
poly(I:C) enhances NK cell killing of transferred B2mΔ/Δ spleno-
cytes and enhances granzyme B expression in NK cells.
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